Characteristics of subjects in the study
| Patients . | Healthy controls (HCs) . | Long-term nonprogressors (LTNPs) . | Typical progressors (TPs) . | Complete responders to HAART (CRs) . |
|---|---|---|---|---|
| Cases, no. | 18 | 18 | 26 | 19 |
| Age, y (range) | 42 (22-55) | 45 (26-53) | 42 (21-56) | 44 (25-54) |
| Sex, no. | ||||
| Male | 9 | 10 | 15 | 10 |
| Female | 9 | 8 | 11 | 9 |
| Median CD4 counts, cells/μL (range) | NA | 789 (514-1284) | 297 (88-480) | 427 (137-925) |
| Median HIV loads, copies/mL (range) | NA | < 500 | 82 500 (2 400-3 880 000) | < 500 |
| Patients . | Healthy controls (HCs) . | Long-term nonprogressors (LTNPs) . | Typical progressors (TPs) . | Complete responders to HAART (CRs) . |
|---|---|---|---|---|
| Cases, no. | 18 | 18 | 26 | 19 |
| Age, y (range) | 42 (22-55) | 45 (26-53) | 42 (21-56) | 44 (25-54) |
| Sex, no. | ||||
| Male | 9 | 10 | 15 | 10 |
| Female | 9 | 8 | 11 | 9 |
| Median CD4 counts, cells/μL (range) | NA | 789 (514-1284) | 297 (88-480) | 427 (137-925) |
| Median HIV loads, copies/mL (range) | NA | < 500 | 82 500 (2 400-3 880 000) | < 500 |
HAART indicates highly active antiretrovial therapy; NA, not applicable.